Search

everythinglearnresearchcommunity

for

Search:↓

A user discusses making DIY dutasteride capsules from powder bought from China, using a mix of MCT oil and propylene glycol. Others warn about the risks of incorrect dosing, potential degradation, and the possibility of receiving fake products.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

A user made a 70/30 ethanol/propylene glycol topical finasteride solution but noticed chunks at the bottom. The discussion focuses on this issue with the DIY hair loss treatment.

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

High DHEA levels may contribute to hair loss by increasing DHT in hair follicles, potentially explaining why finasteride is ineffective for some. Treatments like high-dose dutasteride and RU58841 are suggested, but the underlying cause, such as adrenal issues, should be investigated.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation discusses the ineffectiveness of tablet forms of dutasteride for hair loss due to poor absorption compared to soft gel capsules. It suggests switching to FDA-approved soft gel capsules for better results, as tablets may not adequately suppress DHT levels.

The user is concerned about the legitimacy of online-bought Dutasteride due to its sugary taste and increased urination. Others suggest it looks legitimate but recommend consulting a doctor and possibly testing DHT levels.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

Finasteride and its effects on hair loss, with discussions on the role of estradiol and estrogen. Users debate whether increased estrogen from DHT blockers contributes to hair regrowth, with concerns about potential side effects like chemical castration.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

The conversation discusses the best ethanol and propylene glycol ratio for homemade topical finasteride, with a focus on absorption and drying issues. The user shares their experience using a 50% propylene glycol, 30% ethanol, and 20% water solution, and considers adjusting the ethanol content for better results.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

The user is pausing finasteride for blood donation and is concerned about its effect on DHT levels. They plan to supplement with saw palmetto and pumpkin seed oil during the pause.

The user is starting dutasteride mesotherapy and seeks information on checking serum DHT levels in Germany. They previously tried finasteride but experienced unpleasant side effects.

Dutasteride is hard to get in Europe due to prescription rules, leading some to consider online pharmacies or travel. Users discuss alternatives like private doctors and compare it to finasteride, expressing concerns about side effects and effectiveness.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

The user has been using dutasteride and finasteride but still experiences hair loss and high DHT levels. They plan to try topical finasteride and RU58841 while continuing dutasteride to see if topicals are more effective.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.